146726-10-5Relevant articles and documents
HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
-
Page/Page column 94, (2020/12/30)
(I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET), potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.
Synthesis and diacylglycerol acyltransferase-1 inhibition of azabicyclo[3.1.0]hexane derivatives
Han, Seo-Jung,Lee, Gwi Bin,Kwak, Hyun Jung,Pagire, Suvarna H.,Kim, Ji Young,Pagire, Haushabhau S.,Park, Sung Bum,Chae, Chong Hak,Lee, Joo Yun,Kim, Ki Young,Rhee, Sang Dal,Kim, Hee Youn,Shin, Sun Hye,Bae, Myung Ae,Park, Mi-Jin,Kim, Dooseop,Lee, Duck Hyung,Ahn, Jin Hee
, p. 1586 - 1593 (2015/07/15)
We identified azabicyclo[3.1.0]hexane derivatives that are active diacylglycerol acyltransferase-1 (DGAT)-1 inhibitor. Among the azabicyclo[3.1.0]hexane series, compound 6b showed good in vitro activity toward human DGAT-1, selectivity toward DGAT-2, and
SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS
-
Page/Page column 53-54, (2012/10/07)
Disclosed are CCR2 antagonists of Formula (I)or pharmaceutically acceptable thereof, wherein R1, L1 and A are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.